RealSeq Highlighted at the 66th Annual Valley Fever Meeting

Valley Fever Distribution Map depicts the areas in the US where Valley Fever is endemic. Image Credit: Centers for Disease Control (US CDC)

Sergio Barberan-Soler, CEO RealSeq Biosciences, presented groundbreaking results for the company’s proprietary RiboMarker technology at the 66th Annual Valley Fever (Cocci Study Group) Meeting on April 8-9, 2022.  Valley Fever (VF) is a devastating ting fungal disease that is dramatically increasing in the US and globally due to climate change.  This work was done in collaboration with Dr. Royce Johnson (UCLA/Kern County Valley Fever Institute) a renowned Valley Fever expert whose clinic provided patient samples and support. 

RealSeq was invited to present results demonstrating RiboMarkers’ ability to identify and predict VF dissemination to other organs which is critical because once it disseminates, VF becomes a lifelong affliction with crippling treatment cost burden and diminished quality of life for patients.  According to Dr. Johnson, “this technology could be developed to the holy grail of cocci testing- a testing of control cure.” 

Presentations by VF experts from UC Berkeley, UC Davis, UCLA and the University of Arizona highlighted the rapidly increasing disease prevalence that disproportionately affects “outside workers” such as agricultural and construction workers.  Especially worrisome for those of us on the Central Coast/Valley is the ecological and environmental research confirming that VF is becoming more prevalent here as well. Sergio indicated that this is partly why RealSeq is working so hard to advance the RiboMarker technology with VF as its first target disease although the platform will also be developed for infectious diseases, cancer, and many other indications.   

RealSeq has recently expanded its research capabilities and is currently seeking investors for a seed funding round to further support this exciting work. For more information, contact Sergio: sbarberan@realseqbiosciences.com